U.S. Capital Wealth Advisors LLC Boosts Stock Position in Novo Nordisk A/S $NVO

Key Points

• U.S. Capital Wealth Advisors LLC increased its stake in Novo Nordisk by 109% in Q4 to 193,752 shares (an additional 101,057 shares), valued at about $9.86 million per its SEC filing.
• Novo faces mounting competitive and pricing pressure—from Eli Lilly launching a once‑daily oral GLP‑1 and reports of low‑cost semaglutide generics in India—which heightens near‑term earnings risk.
• Offsetting factors include an EMA update easing Wegovy storage and the oral Wegovy expanding patient demand, but analysts remain mostly cautious with an average "Hold" rating and a $65.56 target.

U.S. Capital Wealth Advisors LLC lifted its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 109.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 193,752 shares of the company's stock after purchasing an additional 101,057 shares during the quarter. U.S. Capital Wealth Advisors LLC's holdings in Novo Nordisk A/S were worth $9,858,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. True Wealth Design LLC increased its holdings in Novo Nordisk A/S by 209.8% in the 3rd quarter. True Wealth Design LLC now owns 443 shares of the company's stock worth $25,000 after buying an additional 300 shares during the period. Guerra Advisors Inc acquired a new position in Novo Nordisk A/S in the 3rd quarter worth approximately $25,000. Strengthening Families & Communities LLC acquired a new position in Novo Nordisk A/S in the 3rd quarter worth approximately $30,000. American National Bank & Trust acquired a new position in Novo Nordisk A/S in the 4th quarter worth approximately $28,000. Finally, Maseco LLP acquired a new position in Novo Nordisk A/S in the 4th quarter worth approximately $29,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Short interest fell sharply in March (about a 19% drop vs. mid‑March), lowering near‑term bearish pressure and reducing potential short‑covering risk. (Source: recent short‑interest report)
• Positive Sentiment: EMA cleared an update allowing Wegovy injections to be delivered at up to 30°C for 48 hours, which should improve distribution flexibility and lower logistics costs in Europe — a modest operational tailwind. Wegovy EMA approval
• Positive Sentiment: Wegovy’s oral formulation appears to be expanding the obesity treatment market by drawing new patients (not just switching injection users), supporting longer‑term demand potential for Novo’s GLP‑1 franchise. CNBC short on Wegovy pill
• Neutral Sentiment: Positive buy‑and‑hold coverage and listings naming Novo as a top growth stock provide long‑term investor support but do not address near‑term competitive or pricing issues. Yahoo piece on growth thesis
• Neutral Sentiment: Novo Holdings (the controlling shareholder) is adding investments outside pharma (e.g., superconductors), which is a corporate/portfolio move with limited direct impact on Novo Nordisk’s operational outlook. Novo Holdings investment
• Negative Sentiment: Eli Lilly launched its once‑daily oral GLP‑1 (Foundayo) broadly in the U.S., increasing competitive pressure on Novo’s market share and pricing power in weight‑loss treatments. Foundayo availability
• Negative Sentiment: Reports of cheap semaglutide generics in India are eroding pricing power in key markets and could weigh on longer‑term revenue if generics expand beyond regional markets. India generics report
• Negative Sentiment: UBS and other analysts warn Q1 results (May 6) will be the first meaningful read on economics at new, lower GLP‑1 price points; coupled with a disappointing CagriSema trial and below‑consensus 2026 guidance earlier this year, this raises near‑term earnings risk. UBS pricing test note
• Negative Sentiment: Media and commentators highlight Eli Lilly pulling ahead in the obesity drug race, which can weigh on sentiment and relative valuation for Novo in the near term. 247WallSt comparison

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Citigroup assumed coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 27th. They issued a "neutral" rating on the stock. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $41.00 price objective (down from $63.00) on shares of Novo Nordisk A/S in a research note on Monday, March 2nd. Nordea Equity Research cut shares of Novo Nordisk A/S to a "hold" rating in a research note on Tuesday, February 24th. CICC Research began coverage on shares of Novo Nordisk A/S in a research note on Friday, January 9th. They set an "outperform" rating and a $73.50 price objective on the stock. Finally, Morgan Stanley raised shares of Novo Nordisk A/S from an "underweight" rating to an "equal weight" rating and set a $40.00 price objective on the stock in a research note on Tuesday, March 3rd. Four equities research analysts have rated the stock with a Buy rating and twenty have given a Hold rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of "Hold" and an average target price of $65.56.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $37.52 on Friday. The stock has a market capitalization of $167.51 billion, a price-to-earnings ratio of 10.81, a PEG ratio of 8.85 and a beta of 0.73. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $81.44. The firm's 50 day simple moving average is $41.03 and its 200-day simple moving average is $48.99. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The firm had revenue of $12.43 billion for the quarter, compared to analysts' expectations of $11.97 billion. Analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Announces Dividend

The business also recently declared a dividend, which was paid on Wednesday, April 8th. Investors of record on Monday, March 30th were paid a $1.2751 dividend. The ex-dividend date of this dividend was Monday, March 30th. This represents a yield of 723.0%. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 50.43%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.